People · Operator
Named in public records as an officer, director or promoter · active 2016–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neon Therapeutics, Inc. | — | Biotechnology | Series D+ | $106.0M | $4.4B | 2016 |
| Rheos Medicines, Inc. | — | Biotechnology | Series B | $27.5M | $1.1B | 2018 |
Stephen Sherwin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Sherwin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Tepper | 1 | 7 |
| ABBIE CELNIKER | 1 | 6 |
| Cary Pfeffer | 1 | 4 |
| Robert Kamen | 1 | 3 |
| Dan Matloff | 1 | 2 |
| Jeffrey Bluestone | 1 | 2 |
| Eric Lander | 1 | 2 |
| Daniella Beckman | 1 | 2 |
| Sanjay Keswani | 1 | 2 |
| Gad Soffer | 1 | 1 |
| Ryan Cohlhepp | 1 | 1 |
| J. Duncan Higgons | 1 | 1 |
| Richard Gaynor, M.D. | 1 | 1 |
| Cary Pfeffer, M.D. | 1 | 1 |
| Robert Ang, M.D. | 1 | 1 |
| Yasir Al-Wakeel | 1 | 1 |
| Hugh Dowd | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.